Richard Daniell

Richard graduated with a BSc from the University of Auckland. He started working for Ivax Pharmaceuticals prior to its acquisition by Teva in 2006.  In Teva he has held various roles including Strategy Director, General Manager, and Chief Operating Officer for the International Markets.  After leading Teva’s integration of Actavis as Chief Integration Office he then led the Generics business in Europe in 2016, and then went on to become head of Europe Commercial in 2017 .

Richard is passionate about healthcare and in particular the impact that affordable access of high quality medicines makes on patients and the wider society. He has a particular interest in #digitalhealth and digital transformation in the industry and the power of data to help drive better healthcare outcomes.

As part Teva's Executive Management team he leads all activities of Teva's Specialty, Generic and OTC business for Europe with a team of functional experts and geographic leads.  With headquarters in The Netherlands, Teva Europe employs approximately 19,055 (commercial plus operations) people in the region and covers 36 countries, including the 27 European Union member states. 

Teva is Europe’s biggest provider of tried-and-trusted generic medicine, a leading provider of Over the Counter (OTC) medicines as well as being a recognised innovator in CNS, respiratory medicines and biopharmaceuticals.